June 22, 2026
The Digital Architect of Immunity: How Immunai’s ‘Plumbing’ is Reshaping AstraZeneca’s Drug Pipeline the-digital-architect-of-immunity-how-immunais-plumbing-is-reshaping-astrazenecas-drug-pipeline

The Digital Architect of Immunity: How Immunai’s ‘Plumbing’ is Reshaping AstraZeneca’s Drug Pipeline

Nana Wu June 22, 2026
In the high-stakes world of pharmaceutical development, where the average cost to bring a new therapy to...
Read More Read more about The Digital Architect of Immunity: How Immunai’s ‘Plumbing’ is Reshaping AstraZeneca’s Drug Pipeline
From Palliative to Curative: FDA Approval of Enhertu Marks a Paradigm Shift in Early-Stage HER2-Positive Breast Cancer Treatment from-palliative-to-curative-fda-approval-of-enhertu-marks-a-paradigm-shift-in-early-stage-her2-positive-breast-cancer-treatment

From Palliative to Curative: FDA Approval of Enhertu Marks a Paradigm Shift in Early-Stage HER2-Positive Breast Cancer Treatment

Dwi Wanna June 22, 2026
The landscape of breast oncology underwent a seismic shift on May 15, as the U.S. Food and...
Read More Read more about From Palliative to Curative: FDA Approval of Enhertu Marks a Paradigm Shift in Early-Stage HER2-Positive Breast Cancer Treatment
A Collision of Fate: How an Unexpected Accident Led One International Student to Her Life-Saving Diagnosis a-collision-of-fate-how-an-unexpected-accident-led-one-international-student-to-her-life-saving-diagnosis

A Collision of Fate: How an Unexpected Accident Led One International Student to Her Life-Saving Diagnosis

Neng Nana June 22, 2026
In the fall of 2023, Joy, a 31-year-old international student from China, arrived in Columbia, South Carolina,...
Read More Read more about A Collision of Fate: How an Unexpected Accident Led One International Student to Her Life-Saving Diagnosis
A New Frontier in Hematology: Teclistamab Redefines Treatment for High-Risk Smoldering Multiple Myeloma a-new-frontier-in-hematology-teclistamab-redefines-treatment-for-high-risk-smoldering-multiple-myeloma

A New Frontier in Hematology: Teclistamab Redefines Treatment for High-Risk Smoldering Multiple Myeloma

Nila Kartika Wati June 22, 2026
In a landmark development for the field of hematology, researchers from the Dana-Farber Cancer Institute have unveiled...
Read More Read more about A New Frontier in Hematology: Teclistamab Redefines Treatment for High-Risk Smoldering Multiple Myeloma
Beyond the Initial Impact: The Convergence of TBI and Alzheimer’s Research and the Promise of Next-Generation Immunotherapy beyond-the-initial-impact-the-convergence-of-tbi-and-alzheimers-research-and-the-promise-of-next-generation-immunotherapy

Beyond the Initial Impact: The Convergence of TBI and Alzheimer’s Research and the Promise of Next-Generation Immunotherapy

Neng Nana June 22, 2026
Traumatic Brain Injury (TBI) is often perceived as a singular event—a collision, a fall, or a strike....
Read More Read more about Beyond the Initial Impact: The Convergence of TBI and Alzheimer’s Research and the Promise of Next-Generation Immunotherapy

You may have missed

the-vanguard-of-genomic-medicine-how-the-broad-institute-is-rewriting-the-human-code

The Vanguard of Genomic Medicine: How the Broad Institute is Rewriting the Human Code

Siti Muinah June 22, 2026
navigating-the-uncharted-wisdom-from-the-breast-cancer-community-on-the-journey-beyond-diagnosis

Navigating the Uncharted: Wisdom from the Breast Cancer Community on the Journey Beyond Diagnosis

Pevita Pearce June 22, 2026
ai-powered-genomic-testing-a-new-frontier-in-ending-the-diagnostic-odyssey-for-rare-diseases

AI-Powered Genomic Testing: A New Frontier in Ending the ‘Diagnostic Odyssey’ for Rare Diseases

Siti Muinah June 22, 2026
fda-shifts-stance-on-rare-disease-gene-therapies-clearing-path-for-regenxbios-navsunli

FDA Shifts Stance on Rare Disease Gene Therapies, Clearing Path for Regenxbio’s Navsunli

Evan Lee Salim June 22, 2026